View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
July 2, 2021

Coronavirus company news summary – Moderna’s Covid-19 vaccine to be produced at Recipharm’s France plant – Australia to trial domestically made mRNA Covid-19 vaccine

By Darcy Jimenez

Moderna and Recipharm , a contract development and manufacturing organisation, confirmed that the European Medicines Agency ’s Committee for Human Medicines has approved the Recipharm Monts site, thereby allowing the manufacture of Moderna ’s Covid-19 vaccine in France. Moderna said that the collaboration will help build its industrial production capacity in the country.

mRNA Victoria, the agency of the Australian State of Victoria government designed to build the State’s mRNA manufacturing and research capabilities, has announced that a domestically produced Covid-19 vaccine candidate will enter Phase I clinical trials in October 2021. Preliminary results from the trial are expected in the first half of next year. mRNA Victoria will fund the Monash Institute of Pharmaceutical Sciences to manufacture the vaccine doses for the trails, establishing Australia’s first foray into mRNA vaccines manufacturing.

Johnson & Johnson has announced that its single-shot Covid-19 vaccine has demonstrated strong, persistent activity against the Delta (India) variant and other SARS-CoV-2 viral variants. Research also found that the durability of the immune responses lasted for at least eight months. The two preprint study summaries have been submitted by the company to bioRxiv, an open access preprint server for the biological sciences operated by Cold Spring Harbor Laboratory .

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology